跳转至内容
Merck
所有图片(1)

文件

C6352

Sigma-Aldrich

CTAP

≥95%

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C51H69N13O11S2
CAS号:
103429-32-9
分子量:
1104.30
MDL號碼:
MFCD00671434
分類程式碼代碼:
12352200
PubChem物質ID:
329775120
NACRES:
NA.32

化驗

≥95%

形狀

powder

UniProt登錄號

Q62923

儲存溫度

−20°C

SMILES 字串

C[C@@H](O)[C@H](NC(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC1(C)C)NC(=O)[C@H](N)Cc5ccccc5)[C@@H](C)O)C(N)=O

InChI

1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33-,35+,36+,37-,38+,39+,40+,41-/m1/s1

InChI 密鑰

OFMQLVRLOGHAJI-FGHAYEPSSA-N

基因資訊

rat ... Pnoc(25516)

Amino Acid Sequence

D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2

應用

CTAP可作为μ-阿片受体 (MOR) 拮抗剂用于：
  • 研究二肽基肽酶4 (DPP4) 抑制剂异亮氨酰-脯氨酰-异亮氨酸 (IPI) 和维格列汀对卡拉胶诱导炎症的抗痛觉过敏作用
  • 研究其在大鼠天敌应激期间对谷氨酸和γ-氨基丁酸 (GABA) 外排的作用
  • 测定在胃泌素释放肽 (Grp+) 神经元活化诱导疼痛阻断中参与的內源性阿片肽

生化／生理作用

CTAP是以生长抑素类似物制备的一种多肽拮抗剂。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

T J Abbruscato et al.
The Journal of pharmacology and experimental therapeutics, 280(1), 402-409 (1997-01-01)
D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP) is a cyclic, penicillamine-containing octapeptide that is structurally similar to somatostatin and displays greater antagonist potency and selectivity for mu-opioid receptors, compared with the classical mu-selective antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2. The aim of this study was to determine whether CTAP
E J Bilsky et al.
The Journal of pharmacology and experimental therapeutics, 277(1), 484-490 (1996-04-01)
Previous studies measuring opioid inhibition of cyclic adenosine monophosphate in SH-SY5Y cells supported the hypothesis that continuous agonist stimulation causes a gradual conversion of the mu opioid receptor to a sensitized or constitutively active state termed mu*. Conversion to mu*
Christine E Engeland et al.
Virology, 460-461, 194-206 (2014-07-11)
Human immunodeficiency virus Gag drives assembly of virions in infected cells and interacts with host factors which facilitate or restrict viral replication. Although several Gag-binding proteins have been characterized, understanding of virus-host interactions remains incomplete. In a series of six
Potency Differences ford-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2as an Antagonist of Peptide and Alkaloid mu-Agonists in an Antinociception Assay
Sterious SN and Walker EA
Journal of Pharmacology and Experimental Therapeutics, 304(1), 301-309 (2003)
Pathology and glia type specific changes of the DPP4 activity in the spinal cord contributes to the development and maintenance of hyperalgesia and shapes opioid signalling in chronic pain states
Kiraly K, et al.
Scientific Reports (2017)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门